Rx Kisspeptin

THE LITERATURE

Kisspeptin References

Every study cited across this site, with PubMed and DOI links. Sort by year or setting.

Back to the researchRead the effects page

How to read these references

Every quantitative claim on this site maps to one of the numbered references below. Where a study sits behind a journal paywall, the PubMed record (and, where available, the DOI) still gives the abstract, authorship and identifiers. This list is the complete source base for the kisspeptin digest — mechanism, the human IVF and amenorrhea trials, the PCOS biomarker data, the pharmacology, and the safety reports. Nothing on the site is asserted that is not traceable here.

  1. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. ↗
  2. Liu X, Lee K, Herbison AE. Kisspeptin excites gonadotropin-releasing hormone neurons through a phospholipase C/calcium-dependent pathway regulating multiple ion channels. Endocrinology. 2008;149(9):4605-4614. ↗
  3. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. ↗
  4. Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014;99(6):E953-E961. ↗
  5. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-3331. ↗
  6. Mills EG, Abbara A, Dhillo WS, et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025;115:105689. ↗
  7. Velmurugan H, Mannava AS, Thangaraju P, Neelambaran K. Kisspeptin and its current clinical status - a systematic review. Curr Med Chem. 2025;32:1313-1322. ↗
  8. Hu KL, Chen Z, Li X, et al. Serum kisspeptin levels in polycystic ovary syndrome: a meta-analysis. J Obstet Gynaecol Res. 2021;47(6):2096-2105. ↗
  9. Tang R, Ding X, Zhu J. Kisspeptin and polycystic ovary syndrome. Front Endocrinol (Lausanne). 2019;10:298. ↗
  10. Abbara A, Al-Memar M, Phylactou M, et al. Kisspeptin in the prediction of pregnancy complications. Front Endocrinol (Lausanne). 2022;13:942664. ↗
  11. Harihar S, Welch DR. KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers? Cancer Metastasis Rev. 2023;42:183-196. ↗
  12. Szeliga A, Podfigurna A, Bala G, Meczekalski B. Decreased neurokinin B as a risk factor of functional hypothalamic amenorrhea. Gynecol Endocrinol. 2023;39:2216313. ↗
  13. Multiple effects of kisspeptin on neuroendocrine, reproduction, and metabolism in polycystic ovary syndrome. J Neuroendocrinol. 2025. ↗
  14. Mills EG, Dhillo WS, et al. Kisspeptin and neurokinin B neuroendocrine pathways in the control of human ovulation. J Neuroendocrinol. 2024. ↗
  15. Li Z, Yang X, Fu R, et al. Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. Nat Commun. 2024. ↗
  16. Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. ↗
  17. Sato K, et al. Potent vasoconstrictor kisspeptin-10 induces atherosclerotic plaque progression and instability: reversal by its receptor GPR54 antagonist. J Am Heart Assoc. 2017;6(4):e005790. ↗
  18. Mills EG, Comninos AN, Dhillo WS, et al. Kisspeptin administration stimulates reproductive hormones but does not affect anxiety in humans. J Clin Endocrinol Metab. 2025;110:dgaf128. ↗